Expanded Approval for ZYTIGA® for the Treatment of Castration-sensitive Prostate Cancer Approval BlogMedical CommunicationsOncology Updates Expanded Approval for ZYTIGA® for the Treatment of Castration-sensitive Prostate Cancer
Lutathera®, a New Treatment Option for Patients with Neuroendocrine Tumors Approval BlogMedical CommunicationsOncology Updates Lutathera®, a New Treatment Option for Patients with Neuroendocrine Tumors
Olaparib, the First PARP Inhibitor to Gain FDA Approval to Treat BRCA-mutant Breast Cancer Approval BlogMedical CommunicationsOncology Updates Olaparib, the First PARP Inhibitor to Gain FDA Approval to Treat BRCA-mutant Breast Cancer
Afatinib receives extended approval for frontline treatment of Patients with Non-resistant EGFR Mutation-positive NSCLC Approval BlogMedical CommunicationsOncology Updates Afatinib receives extended approval for frontline treatment of Patients with Non-resistant EGFR Mutation-positive NSCLC
